Your browser doesn't support javascript.
loading
Controlling oncogenic KRAS signaling pathways with a Palladium-responsive peptide.
Learte-Aymamí, Soraya; Martin-Malpartida, Pau; Roldán-Martín, Lorena; Sciortino, Giuseppe; Couceiro, José R; Maréchal, Jean-Didier; Macias, Maria J; Mascareñas, José L; Vázquez, M Eugenio.
Afiliação
  • Learte-Aymamí S; Centro Singular de Investigación en Química Biolóxica e Materiais Moleculares (CiQUS), Departamento de Química Orgánica, Universidade de Santiago de Compostela, Santiago de Compostela, 15705, Spain.
  • Martin-Malpartida P; Institute for Research in Biomedicine (IRB Barcelona), The Barcelona Institute of Science and Technology, Barcelona, 08028, Spain.
  • Roldán-Martín L; Insilichem, Departament de Química, Universitat Autònoma de Barcelona, Cerdanyola, 08193, Spain.
  • Sciortino G; Insilichem, Departament de Química, Universitat Autònoma de Barcelona, Cerdanyola, 08193, Spain.
  • Couceiro JR; Institute of Chemical Research of Catalonia (ICIQ), The Barcelona Institute of Science and Technology, Tarragona, 43007, Spain.
  • Maréchal JD; Centro Singular de Investigación en Química Biolóxica e Materiais Moleculares (CiQUS), Departamento de Química Orgánica, Universidade de Santiago de Compostela, Santiago de Compostela, 15705, Spain.
  • Macias MJ; Insilichem, Departament de Química, Universitat Autònoma de Barcelona, Cerdanyola, 08193, Spain.
  • Mascareñas JL; Institute for Research in Biomedicine (IRB Barcelona), The Barcelona Institute of Science and Technology, Barcelona, 08028, Spain.
  • Vázquez ME; Institució Catalana de Recerca i Estudis Avançats (ICREA), Passeig Lluís Companys 23, Barcelona, 08010, Spain.
Commun Chem ; 5(1): 75, 2022 Jun 23.
Article em En | MEDLINE | ID: mdl-36697641
ABSTRACT
RAS oncoproteins are molecular switches associated with critical signaling pathways that regulate cell proliferation and differentiation. Mutations in the RAS family, mainly in the KRAS isoform, are responsible for some of the deadliest cancers, which has made this protein a major target in biomedical research. Here we demonstrate that a designed bis-histidine peptide derived from the αH helix of the cofactor SOS1 binds to KRAS with high affinity upon coordination to Pd(II). NMR spectroscopy and MD studies demonstrate that Pd(II) has a nucleating effect that facilitates the access to the bioactive α-helical conformation. The binding can be suppressed by an external metal chelator and recovered again by the addition of more Pd(II), making this system the first switchable KRAS binder, and demonstrates that folding-upon-binding mechanisms can operate in metal-nucleated peptides. In vitro experiments show that the metallopeptide can efficiently internalize into living cells and inhibit the MAPK kinase cascade.

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2022 Tipo de documento: Article